The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Graft-versus-host disease (GVHD) risk with daratumumab (Dara) therapy post allogeneic transplantation (alloHCT) for multiple myeloma (MM).
 
Liana Nikolaenko
No Relationships to Disclose
 
Saurabh Chhabra
No Relationships to Disclose
 
Parameswaran Hari
Honoraria - Amgen; Celgene; Millennium; Novartis; Sanofi; Spectrum Pharmaceuticals
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Celgene; Janssen; Sanofi; Spectrum Pharmaceuticals; Takeda
Research Funding - Celgene (Inst); Millennium (Inst); Onyx (Inst); Spectrum Pharmaceuticals (Inst)
 
Amrita Y. Krishnan
Stock and Other Ownership Interests - Celgene (I); Kite, a Gilead company (I)
Consulting or Advisory Role - Celgene; Janssen Oncology; Kite, a Gilead company; Onyx; Seagen; Takeda
Speakers' Bureau - Celgene; Janssen Oncology; onyx; Takeda
Research Funding - Celgene (Inst); takeda (Inst)
 
Joshua Ryan Richter
Consulting or Advisory Role - Amgen; Celgene; Takeda
Speakers' Bureau - Amgen; Bristol-Myers Squibb; Celgene; Janssen; Takeda
Travel, Accommodations, Expenses - Amgen; Celgene; Janssen; Takeda